Barr Labs erythromycin recall
Generic drug firm initiating Class I recall of approximately 335 bottles of liquid erythromycin ethylsuccinate due to a labeling mix-up that "could have serious health consequences for individuals who are allergic to 'sulfa drugs,'" Pomona, N.Y.-based Barr announced Nov. 26. In addition to erythromycin ethylsuccinate, the bottles being recalled contain sulfisoxazole acetyl, which can cause allergic reactions ranging from "mild discomfort to, in rare cases, life-threatening respiratory distress," Barr said. The nationwide recall to the consumer level involves the stock of the antibiotic received during the previous 30 days with the lot number 1l445AW. . . .
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth